Trial Profile
Randomized, Double-blind, 5 Period Cross Over Study Assessing Lung Function in Healthy Volunteers Following Single Inhalations of GSK573719 Inhalation Powder From Two Configurations of the Novel Dry Powder Inhaler
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GSK
- 22 May 2013 Results presented at the 109th International Conference of the American Thoracic Society.
- 02 Feb 2012 New trial record